Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc reports a purchase of 501,689 ordinary shares on 14 August 2025 under its ongoing buyback programme executed by Merrill Lynch International. The shares were bought on the London Stock Exchange at prices between 1,401.50p and 1,415.50p and will be held as Treasury shares. Since the non-discretionary broker agreement dated 4 June 2025, the company has purchased 23,706,405 ordinary shares. After this transaction GSK will hold 241,840,788 shares in treasury and have 4,073,550,458 ordinary shares in issue (excluding treasury), giving a total of 4,073,550,458 voting rights and treasury shares representing 5.94% of voting rights.
GSK plc executed a purchase of 306,478 ordinary shares of 31.25 pence each on 13 August 2025 at a volume-weighted average price of 1,424.64p per share. The shares were bought through Merrill Lynch International under the company’s existing buyback programme and will be held as Treasury shares.
Since the non-discretionary agreement announced on 4 June 2025, GSK has purchased 23,204,716 ordinary shares. Following this transaction the company holds 241,339,099 ordinary shares in treasury and has 4,074,052,147 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,074,052,147, and the percentage of voting rights attributable to treasury shares is 5.92%.
GSK plc repurchased 495,245 ordinary shares of 31 3/4 pence on 12 August 2025 through its corporate stockbroker Merrill Lynch International, paying between 1,395.50p and 1,405.00p with a volume-weighted average price of 1,401.27p. The purchased shares will be held as treasury stock and form part of the company’s existing buyback programme entered into on 4 June 2025.
Since 4 June 2025 the company has purchased 22,898,238 ordinary shares. Following this trade GSK will hold 241,032,621 ordinary shares in treasury and have 4,074,358,625 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,074,358,625, and ordinary shares held in treasury represent 5.92% of voting rights.
GSK plc reported that multiple senior managers, including CEO Emma Walmsley and CFO Julie Brown, acquired Ordinary Shares under the company’s Share Reward Plan. Each named participant purchased 18 Ordinary Shares (comprised of 9 partnership shares and 9 matching shares) at a price of £14.0845 per share on 11 August 2025. All transactions were executed on the London Stock Exchange (XLON). The report lists several other executives and senior officers making identical purchases under the same plan; the disclosures are routine notifications of employee share-plan acquisitions.
GSK plc announced it repurchased 494,426 ordinary shares on 11 August 2025 at prices between 1,400.00p and 1,413.50p, with a volume‑weighted average price of 1,405.33p. The shares were bought through Merrill Lynch International on the London Stock Exchange and will be held as Treasury shares.
This purchase is part of an existing buyback programme (non‑discretionary agreement announced 4 June 2025). Since 4 June 2025 the Company has repurchased 22,402,993 ordinary shares. After the transaction GSK holds 240,537,376 Treasury shares and has 4,074,853,870 ordinary shares in issue (excluding Treasury shares). The Company reports total voting rights of 4,074,853,870 and states Treasury shares represent 5.90% of voting rights; shareholders may use the total voting rights figure as the denominator for notification calculations.
GSK announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged 12 years and older (weighing ≥45 kg), with a Prescription Drug User Fee Act action date set for December 2025. The submission is supported by the EAGLE-1 phase III trial published in The Lancet, where oral gepotidacin (two doses of 3,000 mg) achieved a 92.6% success rate at the urogenital site (187/202) versus 91.2% (186/204) for intramuscular ceftriaxone plus oral azithromycin, meeting non-inferiority. No failures from bacterial persistence were reported and no serious drug-related adverse events were observed; the most common adverse reactions were mild to moderate gastrointestinal events. Gepotidacin previously received US approval as Blujepa for uncomplicated urinary tract infection and its development was funded in part by BARDA and the US Department of Defense.
GSK plc completed a tranche of its announced share buyback on 08 August 2025, purchasing 497,923 ordinary shares at prices between 1,389.50p and 1,405.50p, with a volume-weighted average price of 1,397.58p. The shares were bought through Merrill Lynch International under the non-discretionary broker agreement entered into on 4 June 2025 and will be held as Treasury shares. Since 4 June 2025 the company has purchased 21,908,567 ordinary shares under this programme.
Following this purchase GSK will hold 240,042,950 ordinary shares in treasury and have 4,075,348,296 ordinary shares in issue (excluding Treasury shares). The company states the total number of voting rights is 4,075,348,296, and that ordinary shares held in treasury represent 5.89% of voting rights for DTR calculation purposes.
GSK has monetised its licence with CureVac through a settlement linked to CureVac’s 7 Aug 2025 agreement with BioNTech. The company will receive an immediate $370 million payment ($320 m cash) and collect a 1 % royalty on all 2025-onward US sales of Pfizer/BioNTech influenza, COVID-19 and combination mRNA vaccines.
The settlement also amends the CureVac licence, materially reducing future royalties that GSK would owe on its own mRNA pipeline products.
- Contingent upside: if BioNTech’s proposed acquisition of CureVac closes, GSK gains an extra $130 m cash, a further 1 % royalty on ex-US sales of the same vaccines and lower milestone obligations.
- Accounting: the $370 m is booked as other operating income (adjusting item) in Q3-2025; future royalties flow through total & core results.
- Litigation: GSK’s separate patent suits against Pfizer/BioNTech continue in the US and Europe.
- Strategic: GSK will tender its ≈16.6 m CureVac shares under the forthcoming offer.
The deal delivers near-term cash, creates recurring high-margin royalty streams and lowers eventual COGS for GSK’s own mRNA vaccines, though additional proceeds depend on the CureVac acquisition closing and legal uncertainties persist.
GSK plc filed a Form 6-K disclosing the latest tranche of its ongoing share buy-back programme. On 7 August 2025 the company repurchased 502,466 ordinary shares (31¼ p nominal) through Merrill Lynch International at prices between 1,361.00 p and 1,385.50 p, delivering a volume-weighted average price of 1,376.94 p.
These shares will be held in treasury, lifting treasury holdings to 239,545,027 shares, equal to 5.88 % of total voting rights. Shares in issue ex-treasury now stand at 4,075,843,458. Since the non-discretionary agreement with the broker began on 4 June 2025, GSK has acquired 21,410,644 shares under the programme.
The disclosure provides investors with the denominator for holdings notifications under UK Listing Rule DTR 5 and confirms that the buy-back remains within the previously announced authorisation.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
